Zoledronate disodium. Treatment of tumor-induced hypercalcemia usan angiogenesis inhibitor

Drugs of the Future

Volumn 25, Issue 3, 2000, Pages 259-268

  Sorbera, L A ^a   Rabasseda, X ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MOUSE; MULTICENTER STUDY; NONHUMAN; PAGET BONE DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034008123     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.03.569207     Document Type: Review

References (40)

1. Jaeggi, K.A., Widler, L. (Ciba-Geigy Corp.). Substituted alka-nediphosphonic acids and pharmaceutical use. AU 8781453, EP 0275821, JP 1988150291, US 4939130.
2. Raisz, L.G. Physiology and pathophysiology of bone remodeling. Clin Chem 1999, 45: 1353-8.
3. Morton, A.R. The role of bisphosphonates in patients with bony metastases. Cancer J 1995, 8: 231-3.
4. Delmas, P.D. Bisphosphonates in the treatment of bone diseases. New Engl J Med 1996, 335: 1836-7.
5. Green, J.R., Muller, K., Jaeggi, K.A. Preclinical pharmacology of CGP 42,446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9: 745-51.
6. Seltenmeyer, Y., Green, J.R. A comparison of the antiresorptive potency of various bisphosphonates in vivo with their inhibitory effect in vitro on squalene synthase and cellular sterol synthesis. Bone 1997, 20(4, Suppl.): Abst P376.
7. Pataki, A., Müller, K., Green, J.R., Ma, Y.F., Li, Q.N., Lee, W.S.S. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997, 249: 458-68.
8. Hiraga, T., Hata, K., Nishimura, R., Takeda, S., Dallas, M., Mundy, G.R., Yoneda, T. Combined treatment with bisphosphonates and oral UFT inhibits bone and soft organ metastases and prolongs survival. J Bone Miner Res 1999, 14(Suppl. 1): Abst T039.
9. Glatt, M., Pataki, A. Longterm zoledronate treatment prevents bone loss in estrogen-deficient rats. J Bone Miner Res 1999, 14(Suppl. 1): Abst SA373.
10. Binkley, N., Kimmel, D., Bruner, J., Haffa, A., Davidowitz, B., Meng, C., Schaffer, V., Green, J. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998, 13: 1775-82.
11. O'Rourke, C., Bare, S., Kimmel, D., Binkley, N., Schaffer V., Green, J. Zoledronate (CGP 42,446) suppresses turnover in cortical bone of the ovariectomized non-human primate. J Bone Miner Res 1997, 12(Suppl. 1): Abst S481.
12. Pysklywec, M.W., Moran, E.L., Bogoch, E.R. Zoledronate (CGP 42,446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. J Orthop Res 1997, 15:858-61.
13. Fornasier, V.L., Moran, E.L., Bogoch, E.R. The bisphosphonate zoledronate modifies the intraosseous response of cell populations in experimental inflammatory arthritis (EIA). J Bone Miner Res 1997, 12(Suppl. 1): Abst S639.
14. Podworny, N.V., Kandel, R.A., Renlund, R.C., Grynpas, M.D. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 1999, 26: 1972-82.
15. Bogoch, E.R., Moran, E.L., Reiner, A., Poole, A.R. Degradation of cartilage type II collagen in experimental inflammatory arthritis (EIA) may be prevented by CGP 42,446. Bone 1995, 17(6): 598.
16. Green, J.R., Clay, V., Richardson, J., Hassan, I.F. The effect of zoledronate and pamidronate on the intestinal permeability barrier in vitro and in vivo. Int J Pharm 1997, 153: 59-66.
17. Arden-Cordone, M., Siris, E.S., Lyles, K.W., Knieriem, A., Newton, R.A., Schaffer, V., Zelenakas, K. Antiresorptive effects of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 1997, 60: 415-8.
18. Buckler, H., Fraser, W., Hosking, D. et al. Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study. Bone 1999, 24: 81S-5S.
19. Zelenakas, K., Buckler, H., Schaffer, V., Richardson, P. A double-blind placebo-controlled trial using intravenous CGP-42446 in patients with Paget's disease of bone. Bone 1995, 17(6): 618.
20. Siris, E. Zoledronate in the treatment of Paget's disease. Br J Clin Pract 1996, Suppl. 87: 19-20.
21. Garnero, P., Gineyts, E., Schaffer, A.V., Seaman, J., Delmas, P.D. Measurement of urinary excretion of monisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 1998, 41: 354-60.
22. Berenson, J.R., Lipton, A., Rosen, L.S., Savage, A., Kowalski, M., Heffernan, M., Knight, R. Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases. Blood 1996, 88(10, Suppl. 1): Abst 2334.
23. Fulfaro, F., Casuccio, A., Ticozzi, C., Ripamonti, C. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 1998, 78: 157-69.
24. Lipton, A., Berenson, J., Porter, L., Rosen, L., Levy, E., Knight, R. Zoledronate: Phase II study in patients with osteolytic bone metastases. Cancer Invest 1999, 17(Suppl. 1): 12.
25. Lipton, A., Berenson, J., Knight, R., Grace, H., Levy, E.R. Phase II trial of zoledronate vs. pamidronate in multiple myeloma and breast cancer. 17th Chemother Found Symp Innovative Cancer Chemother Tomorrow (Nov 3-6, New York) 1999, Abst 53.
26. Body, J.J., Lortholary, A., Romieu, G., Vigneron, A.M., Ford, J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999, 14: 1557-61.
27. Lipton, A., Berenson, J., Rosen, L., Harvey, H., Kowalski, M., Hefferman, M., Knight, R., Seaman, J. Phase I study of zoledronate (CGP 42446) in patients with osteolytic bone metastases. Ann Oncol 1996, 7(Suppl. 5): Abst 639P.
28. Lipton, A. Zoledronate in the treatment of osteolytic bone metastases. Br J Clin Pract 1996, Suppl. 87: 21.
29. Rosen, L.S., Lipton, A., Savage, A., Kowalski, M., Miller, J.A., Knight, R., Seaman, J., Berenson, J.R. Phase I trial of zoledronate (CGP 42446), a new bisphosphonate, in patients with osteolytic bone lesions. Proc Amer Soc Clin Oncol 1996, 15: Abst 1570.
30. Novartis files regulatory dossiers for Zometa around the world. DailyDrugNews.com (Daily Essentials) December 27, 1999.
31. Novartis bisphosphonate (Zometa) granted priority review status. DailyDrugNews.com (Daily Essentials) February 11, 2000.
32. Binkley, N., Bruner, J., Haffa, A., Davidowitz, B., Kimmel, D., Schaffer, V., Green, J. Zoledronate (CGP 42,446) prevents persistent absolute osteopenia after ovariectomy in primates. J Bone Miner Res 1997, 12(Suppl. 1): Abst S480.
33. Podworny, N., Kandel, R., Renlund, R., Grynpas, M. The effect of zoledronate on cartilage and bone quality of the joint in a rabbit model of inflammatory arthritis. J Bone Miner Res 1997, 12(Suppl. 1): Abst F280.
34. Bare, S., Kimmel, D., Binkley, N., Schaffer, V., Green, J. Zoledronate (CGP 42,446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate. J Bone Miner Res 1997, 12(Suppl. 1): Abst S482.
35. Green, J.R., Hassan, I., Jaeggi, K.A. The intestinal tolerability of the bisphosphonate CGP 42,446: Effects in vitro on Caco-2 cell monolayers and in vivo on perfused rat ileal loops. Bone Miner 1994, 25(Suppl. 1): Abst 46.
36. Pataki, A., Green, J.R., Müller, K., Schneider, R., Studer, A., Jaeggi, K.A. A histomorphometric comparison of the effects on rat bone of short-term treatment with the two bisphosphonates CGP 42,446 and pamidronate: Static parameters. Bone Miner 1994, 25(Suppl.1): Abst 12.
37. Green, J. Zoledronate: The preclinical pharmacology. Br J Clin Pract 1996, Suppl. 87: 16-8.
38. Podworny, N., Kandel, R., Renlund, R., Grynpas, M. The effect of the bisphosphonate CGP 42,446 on the joint in a rabbit model of inflammatory arthritis. Bone 1995, 17(6): 601.
39. Lipton, A., Berenson, J., Savage, A., Kowalski, M., Seaman, J., Knight, R. The effects of the bisphosphonate, zoledronate, when administered as a short intravenous infusion in patients with bone metastases: A phase I study. Proc Amer Soc Clin Oncol 1997, 16: Abst 848.
40. Hupkes, M., Givant, F. Zoledronate, a new 3rd generation bisphosphonate: Implications for nursing practice. Eur J Cancer 1999, 35(Suppl. 4): Abst 152.